PANBELA THERAPEUTICS INC (PBLA) Stock Price, Quote, News and Overview
NASDAQ:PBLA - Nasdaq - US69833W4042 - Common Stock - Currency: USD
PBLA Quote, Performance and Key Statistics
PANBELA THERAPEUTICS INC
NASDAQ:PBLA (3/6/2024, 8:15:57 PM)
After market: 1.04 -0.07 (-6.31%)1.11
-0.12 (-9.76%)
The current stock price of PBLA is 1.11 USD. In the past month the price decreased by -7.5%. In the past year, price decreased by -99.73%.
PBLA Latest News, Press Releases and Analysis
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024
PBLA stock results show that Panbela Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the second quarter...
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
PBLA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.34 | 310.40B | ||
| AMGN | AMGEN INC | 14.78 | 152.67B | ||
| GILD | GILEAD SCIENCES INC | 21.88 | 120.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 859.61 | 112.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.04 | 75.06B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.75B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.13B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.16B | ||
| NTRA | NATERA INC | N/A | 23.27B | ||
| BIIB | BIOGEN INC | 8.95 | 21.31B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.49B |
Related stock screener links
About PBLA
Company Profile
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 6 full-time employees. The company went IPO on 2014-07-29. The firm is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The firm's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
Company Info
PANBELA THERAPEUTICS INC
712 Vista Blvd # 305
Waconia MINNESOTA 55387 US
CEO: Jennifer K. Simpson
Employees: 6
Company Website: https://panbela.com/
Phone: 19524791196
PBLA FAQ
What is the stock price of PBLA?
The current stock price of PBLA is 1.11 USD.
What is the symbol for PANBELA THERAPEUTICS INC stock?
The exchange symbol of PANBELA THERAPEUTICS INC is PBLA and it is listed on the Nasdaq exchange.
On which exchange is PBLA stock listed?
PBLA stock is listed on the Nasdaq exchange.
Is PBLA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PBLA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PBLA.
Does PBLA stock pay dividends?
PBLA does not pay a dividend.
When does PBLA stock report earnings?
PBLA will report earnings on 2024-05-02, after the market close.
What is the Price/Earnings (PE) ratio of PBLA?
PBLA does not have a PE ratio as the earnings reported over the last twelve months were negative (-4010.88).
What is the Short Interest ratio of PBLA stock?
The outstanding short interest for PBLA is 0% of its float.
PBLA Technical Analysis
PBLA Financial Highlights
Over the last trailing twelve months PBLA reported a non-GAAP Earnings per Share(EPS) of -4010.88. The EPS decreased by -67.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PBLA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PBLA. The Buy consensus is the average rating of analysts ratings from 8 analysts.